Quantitative MRI for Myelofibrosis
Key claim: Functional MRI parameters are being developed and validated as biomarkers to quantify disease extent and treatment response in patients with myelofibrosis.
Abstract
This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.
Why this matters
Fibrosis-defining subtypes (PMF and secondary MF) rely on serial bone marrow biopsy for staging and response assessment, a painful and sampling-limited procedure. Adding quantitative functional MRI to the emerging non-invasive imaging arsenal (CCR2 PET, 18F-FAPI PET/MRI, pSWE) offers a whole-organ, repeatable readout of fibrotic burden and treatment effect that could refine natural-history tracking and trial endpoints across the MF spectrum.